Published 1 hour ago • loading... • Updated 41 minutes ago
Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks
WHO said 20,000 doses will go to a Phase 3 trial and 50,000 to health workers as Congo battles a fast-spreading outbreak.
On Thursday, the World Health Organization and partners announced that Congo will receive 70,000 doses of the Ervebo vaccine to contain the fastest-spreading Ebola outbreak in history.
Driven by the rare Bundibugyo virus, the outbreak has resulted in 2,476 deaths among 5,208 confirmed cases, with the case fatality rate averaging 47.5% and reaching up to 70% in North Kivu province.
The allocation includes 20,000 doses for a Phase 3 clinical trial to understand the vaccine's impact on Bundibugyo virus, with 50,000 doses for frontline workers; early laboratory data suggests it may provide protection.
WHO Director-General Tedros Adhanom Ghebreyesus described the approval as an "important example of global solidarity in action," while the International Coordinating Group will release doses immediately upon Congo's request.
Experts note the virus is spreading three times faster than the 2014–2016 West Africa outbreak, which caused more than 11,000 deaths, with transmission likely beginning in Mongbwalu as early as February.
The Congo receives tens of thousands of doses of vaccine for the fight against the Ebola epidemic. However, the vaccine is not approved for the Ebola variant that is rampant there.
The World Health Organization deploys doses of Ervebo vaccine in the DRC to try to stem a particularly deadly Ebola epidemic in the face of the Ebola epidemic in the Republic